Nuclidium is setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer treatment and diagnosis. Our flexible CuTraceTM platform combines copper radiometals with a variety of highly specific cancer-targeting molecules to rapidly develop novel therapeutic and diagnostic programs. The resulting product portfolio leverages the unique properties of copper to achieve an improved safety and efficacy profile with advantageous economics for hospitals and patients. Nuclidium’s differentiated “diagnostic to therapeutic” approach de-risks our development pathway. With innovation as our core, we overcome supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities. We are a diverse and interdisciplinary team focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients.
Location: Switzerland
Employees: 1-10
Total raised: $101.75M
Founded date: 2017
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.07.2025 | Series B | $99.15M | Angelini V... |
| 28.03.2022 | Grant | $2.6M | - |
Mentions in press and media 7
| Date | Title | Description |
| 12.07.2025 | Swiss Biotech Secures Major Funding for Advanced Cancer Treatments | Swiss biotech firm NUCLIDIUM secured €84 million in Series B funding. This significant capital injection propels its proprietary copper-based theranostic platform. The company targets advanced cancer diagnosis and treatment. Funds will acce... |
| 11.07.2025 | NUCLIDIUM raises €84M Series B to advance copper-based cancer therapies | NUCLIDIUM, a Swiss clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer, has raised €84 million Series B funding. Leveraging copper is... |
| 10.07.2025 | Swiss BioTech platform NUCLIDIUM raises €84 million for the diagnosis and treatment of cancer | Basel-based NUCLIDIUM, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced the successful closing of its Series B financing round, raising €84 million. The round was led b... |
| 10.07.2025 | Nuclidium Raises €84M in Series B Funding | Nuclidium, a Basel, Switzerland-based clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, raised €84M in Series B funding The round was co-led by Angelini Ventures, Kurma Growth Opportuniti... |
| 10.07.2025 | CHF 79 million to advance Nuclidium’s copper-based radiopharmaceutical platform | NUCLIDIUM’s differentiated platform links tumor-targeting molecules with copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – to address current limitations in radiotheranostics, such as suboptimal clinical efficacy... |
| 21.10.2024 | A new step in the clinical development | Based-based company NUCLIDIUM announced the imaging of the first patient in a Phase 1 clinical trial for its radiotracer, 61Cu-NuriPro™, aimed at diagnosing and staging prostate cancer. The phase 1 clinical trial aims at evaluating the com... |
| 27.03.2023 | Nuclidium secures grant to launch phase 1 clinical trial |